Narcolepsy — Symptoms, Causes & Treatment | MyMedicPlus

Narcolepsy is a chronic neurological disorder causing excessive daytime sleepiness (EDS) with uncontrollable episodes of falling asleep. Type 1 narcolepsy involves loss of orexin (hypocretin)-producing neurons and is associated with cataplexy (sudden muscle weakness triggered by emotion). Type 2 lacks cataplexy with normal or borderline orexin levels. Prevalence is approximately 1 in 2,000. Narcolepsy is a rare, chronic neurological sleep disorder characterised by dysregulation of the sleep-wake boundary, resulting in intrusion of rapid eye movement (REM) sleep elements into wakefulness and fragmentation of nocturnal sleep. Type 1 narcolepsy — the classic form — is caused by selective destruction of approximately 85-90% of the lateral hypothalamic orexin (hypocretin)-producing neurons, most likely through autoimmune mechanisms in genetically susceptible individuals. Orexin is essential for stabilising wake state and preventing inappropriate REM sleep intrusion. Type 2 narcolepsy shares the same clinical symptoms except cataplexy and has normal or borderline-low CSF hypocretin-1 levels. Narcolepsy affects approximately 1 in 2,000 people (prevalence 0.03-0.05%) — making it as common as multiple sclerosis — but remains drastically underdiagnosed, with a mean diagnostic delay of 8-15 years from symptom onset. Onset typically occurs in the second decade of life, often triggered by an environmental event in genetically susceptible individuals.

Type 1 narcolepsy is caused by autoimmune destruction of hypocretin/orexin-producing neurons in the lateral hypothalamus. Strong association with HLA-DQB1*06:02 genotype (present in 95% of Type 1). Environmental triggers may include H1N1 influenza infection or vaccination (AS03-adjuvanted Pandemrix). Most cases are sporadic; family history is present in 1-2%. Type 2 etiology is poorly understood. The autoimmune hypothesis for Type 1 narcolepsy is strongly supported by: the extreme genetic association with HLA-DQB1*06:02 (present in 95% of Type 1 narcolepsy versus 12-25% of the general population, conferring a 200-fold relative risk); association with HLA-DQA1*01:02 in trans with HLA-DQB1*06:02; T-cell receptor gene polymorphisms; and direct demonstration of autoreactive CD4+ and CD8+ T cells targeting orexin neurons in narcolepsy patients (2019). Environmental triggers that may precipitate autoimmune attack in genetically susceptible individuals include: influenza A (H1N1) infection and — critically documented by multiple national pharmacovigilance studies — the AS03-adjuvanted pandemic influenza vaccine Pandemrix used in the 2009-2010 H1N1 pandemic, associated with a 5-13 fold increased narcolepsy risk in children in Finland, Sweden, and the UK. Streptococcal and other upper respiratory infections are also associated with narcolepsy onset in case series.

Excessive daytime sleepiness is universal: irresistible sleep attacks lasting minutes, refreshing briefly then recurring. Cataplexy (Type 1 only): sudden bilateral muscle atonia triggered by strong emotions (laughter, surprise) causing knee buckling or complete falls while remaining conscious. Sleep paralysis (unable to move while falling asleep or waking), hypnagogic hallucinations (vivid dream-like experiences at sleep onset), and disrupted nocturnal sleep complete the pentad. The narcolepsy pentad comprises five symptoms — not all present in every patient. Excessive daytime sleepiness (EDS) — universal: irresistible sleep attacks occurring at inappropriate times (eating, driving, conversation, during work), each lasting 10-20 minutes and often refreshing briefly; the ESS (Epworth Sleepiness Scale) score typically exceeds 15 (maximum 24) in narcolepsy. Cataplexy (Type 1 narcolepsy, virtually pathognomonic): sudden bilateral loss of muscle tone triggered by strong positive emotions — laughter, surprise, excitement — causing head drooping, jaw slackening, knee buckling, or complete falls lasting seconds to 2 minutes while fully conscious and with recall; episodes may be partial (affecting only the face or knees) or complete (full postural collapse). Sleep paralysis (40-80%): transient inability to move during sleep-wake transitions lasting seconds to 2 minutes — often frightening; may be accompanied by vivid hypnagogic hallucinations. Hypnagogic/hypnopompic hallucinations (60-80%): vivid visual, auditory, or tactile experiences at sleep onset or waking. Disrupted nocturnal sleep with frequent awakenings, vivid dreams, and sleep behaviour disorder.

Overnight polysomnography (PSG) followed by Multiple Sleep Latency Test (MSLT) is the standard diagnostic workup. MSLT measures mean sleep onset latency (under 8 minutes) and demonstrates 2 or more sleep-onset REM periods (SOREMPs) across 5 nap opportunities. CSF hypocretin-1 level below 110 pg/mL is diagnostic for Type 1 narcolepsy. HLA-DQB1*06:02 typing is supportive but not diagnostic. The diagnostic protocol requires overnight polysomnography (PSG) followed by next-day Multiple Sleep Latency Test (MSLT), performed after ensuring adequate sleep opportunity and after a 2-week washout from REM-suppressing medications (SSRIs, TCAs, modafinil, sodium oxybate). PSG assesses REM latency, periodic limb movements, sleep apnoea, and total sleep time, serving as a baseline for next-day testing. MSLT: the patient undergoes 5 nap opportunities at 2-hour intervals; mean sleep latency below 8 minutes (reflecting pathological sleepiness) and 2 or more sleep-onset REM periods (SOREMPs) — entering REM within 15 minutes of sleep onset in 2 or more naps — meet criteria for narcolepsy; sensitivity approximately 80%, specificity approximately 90%. CSF hypocretin-1 measurement: hypocretin-1 below 110 pg/mL (one-third of mean normal control values) is pathognomonic for Type 1 narcolepsy — specificity approaches 99%; it is diagnostic without MSLT when positive and avoids medication washout. HLA-DQB1*06:02 testing supports but is not diagnostic (present in 20% of the general population without narcolepsy).

EDS management: modafinil or armodafinil (wakefulness-promoting agents, first-line); sodium oxybate (GHB, taken at night) is the only therapy approved for both EDS and cataplexy and produces the deepest improvement in all narcolepsy symptoms. Pitolisant (H3 receptor antagonist) is an alternative non-scheduled option. Scheduled daytime naps (20 minutes, 1-2 per day) reduce sleep attacks. Cataplexy: sodium oxybate, SSRIs, SNRIs, or venlafaxine. Sodium oxybate (Xyrem, GHB — gamma-hydroxybutyrate): the most effective pharmacotherapy addressing both EDS and cataplexy simultaneously — the only drug licensed for both indications. Taken orally in two divided nocturnal doses (starting 4.5 g/night, titrated to 6-9 g/night); it consolidates fragmented nocturnal sleep, suppresses cataplexy within days to weeks, and significantly reduces EDS; takes 4-8 weeks to reach full effect. Major side effects: nausea, nocturnal enuresis, and dose-related sedation; controlled substance due to abuse potential; contraindicated with alcohol, benzodiazepines, and sedating medications. Modafinil/armodafinil: wakefulness-promoting agents (mechanism: weak dopamine reuptake inhibition plus histamine activation); first-line for EDS where sodium oxybate is unsuitable — well tolerated but does not address cataplexy. Pitolisant (Wakix, Ozawade): H3 receptor inverse agonist increasing brain histamine activity; non-controlled drug, useful when sodium oxybate is contraindicated or refused — addresses both EDS and cataplexy. SSRIs (fluoxetine 20-40 mg) and venlafaxine 75-150 mg suppress cataplexy by inhibiting REM sleep — second-line for cataplexy when sodium oxybate is not tolerated.

Narcolepsy significantly impairs quality of life, occupational performance, driving safety, and social functioning. Automatic behavior (continuing activity without conscious awareness during microsleeps) creates safety risks. Cataplexy can cause falls and injury. Depression affects up to 30% of patients. Mean diagnostic delay is 8-15 years from symptom onset due to under-recognition. Obesity is more common in narcolepsy Type 1. The socioeconomic and safety burden of narcolepsy is profound. Road traffic accidents and near-misses are 2-7 times more frequent in individuals with inadequately treated narcolepsy — most licensing authorities suspend driving privileges until EDS is demonstrably controlled on treatment. Work-related accidents and productivity loss are significant — automatic behaviour (continuing complex activities during microsleep episodes without awareness or memory) creates safety hazards in occupations involving machinery, patient care, or high-risk environments. Academic and occupational underachievement from EDS and cognitive dysfunction (poor concentration, impaired working memory from sleep fragmentation) leads to career truncation. Depression affects 30-50% of narcolepsy patients — both as a primary co-morbidity related to orexin deficiency and as a secondary response to the profound social, occupational, and personal limitations imposed by the disorder. Weight gain and obesity are more common in Type 1 narcolepsy — orexin promotes energy expenditure, and its loss combined with reduced physical activity contributes to metabolic complications.

There is no prevention for narcolepsy as it results from autoimmune neuronal loss. Management strategies include scheduled short daytime naps, strict regular sleep schedule, avoiding alcohol and sleep deprivation, and informing employers of the diagnosis for reasonable workplace accommodations. Driving restrictions apply until EDS is adequately controlled. Patient support groups and mental health support are important adjuncts. As narcolepsy results from autoimmune destruction of orexin neurons in genetically susceptible individuals, there is currently no proven primary prevention. Secondary prevention — minimising symptom impact — focuses on: structured sleep scheduling (fixed bedtime and wake time 7 days a week, with planned daytime naps of 15-20 minutes at regular times — reducing sleep pressure and sleep attacks); strict avoidance of alcohol (exacerbates sleepiness and cataplexy) and sleep deprivation; avoiding shift work and occupations with continuous vigilance requirements before adequate symptom control. Driving restrictions must be discussed at diagnosis — DVLA notification is required in the UK and equivalent organisations internationally; most allow return to driving after documented treatment response. Psychological support (CBT adapted for narcolepsy, coping strategy training) and peer support groups (Narcolepsy UK, Wake Up Narcolepsy) improve self-efficacy and quality of life. Workplace and school accommodations — flexible scheduling, permission for scheduled naps, quiet resting areas — are important adjustments reducing disability impact.

See your GP or request referral to a sleep medicine specialist if you experience: recurrent irresistible sleep episodes occurring at inconvenient or dangerous times (while eating, during a conversation, at work); sudden episodes of muscle weakness in the knees or face triggered by strong emotion such as laughter or surprise — this is cataplexy, the hallmark of narcolepsy Type 1, and is pathognomonic of orexin deficiency. Seek urgent evaluation if you have fallen asleep while driving or had a near-miss — you should not drive until fully assessed and treated. Narcolepsy has a mean diagnostic delay of 8–15 years because symptoms are often attributed to depression, shift work, or other sleep disorders; if standard investigations for sleep apnea are negative but EDS persists, request specialist referral for polysomnography plus MSLT (Multiple Sleep Latency Test). Notify your DVLA or licensing authority when diagnosed — most jurisdictions require medical clearance before driving can resume. For children under 18 with suspected narcolepsy after AS03-adjuvanted Pandemrix vaccination, urgent paediatric neurology referral is required as vaccine-associated narcolepsy is a recognised regulatory compensation case.